US20230414296A1 - Biological tissue position location and marking - Google Patents
Biological tissue position location and marking Download PDFInfo
- Publication number
- US20230414296A1 US20230414296A1 US18/243,988 US202318243988A US2023414296A1 US 20230414296 A1 US20230414296 A1 US 20230414296A1 US 202318243988 A US202318243988 A US 202318243988A US 2023414296 A1 US2023414296 A1 US 2023414296A1
- Authority
- US
- United States
- Prior art keywords
- marking
- tip
- patch
- substance
- marking substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims abstract description 114
- 239000000126 substance Substances 0.000 claims description 178
- 239000000758 substrate Substances 0.000 claims description 77
- 230000005291 magnetic effect Effects 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 17
- 230000000887 hydrating effect Effects 0.000 claims description 14
- 238000001356 surgical procedure Methods 0.000 claims description 13
- 230000000087 stabilizing effect Effects 0.000 claims description 11
- 230000002745 absorbent Effects 0.000 claims description 10
- 239000002250 absorbent Substances 0.000 claims description 10
- 239000000560 biocompatible material Substances 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 6
- 230000000149 penetrating effect Effects 0.000 claims description 4
- 238000002847 impedance measurement Methods 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 9
- 239000003550 marker Substances 0.000 description 46
- 239000000975 dye Substances 0.000 description 31
- 238000002679 ablation Methods 0.000 description 12
- 230000003902 lesion Effects 0.000 description 12
- 238000013507 mapping Methods 0.000 description 12
- 230000000747 cardiac effect Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000001174 endocardium Anatomy 0.000 description 7
- 229920000954 Polyglycolide Polymers 0.000 description 4
- 239000004633 polyglycolic acid Substances 0.000 description 4
- 238000007674 radiofrequency ablation Methods 0.000 description 4
- 210000001013 sinoatrial node Anatomy 0.000 description 4
- 230000003126 arrythmogenic effect Effects 0.000 description 3
- 210000001992 atrioventricular node Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002594 fluoroscopy Methods 0.000 description 3
- 230000000574 ganglionic effect Effects 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000005248 left atrial appendage Anatomy 0.000 description 2
- 229920002791 poly-4-hydroxybutyrate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 239000004627 regenerated cellulose Substances 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004962 Polyamide-imide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical class [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001235 gentian violet Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- RSMUVYRMZCOLBH-UHFFFAOYSA-N metsulfuron methyl Chemical compound COC(=O)C1=CC=CC=C1S(=O)(=O)NC(=O)NC1=NC(C)=NC(OC)=N1 RSMUVYRMZCOLBH-UHFFFAOYSA-N 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920002312 polyamide-imide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3478—Endoscopic needles, e.g. for infusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
- A61B34/20—Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/1815—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
- A61B17/205—Vaccinating by means of needles or other puncturing devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00022—Sensing or detecting at the treatment site
- A61B2017/00026—Conductivity or impedance, e.g. of tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00022—Sensing or detecting at the treatment site
- A61B2017/00039—Electric or electromagnetic phenomena other than conductivity, e.g. capacity, inductivity, Hall effect
- A61B2017/00044—Sensing electrocardiography, i.e. ECG
- A61B2017/00048—Spectral analysis
- A61B2017/00053—Mapping
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00243—Type of minimally invasive operation cardiac
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00243—Type of minimally invasive operation cardiac
- A61B2017/00247—Making holes in the wall of the heart, e.g. laser Myocardial revascularization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00345—Vascular system
- A61B2018/00351—Heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00345—Vascular system
- A61B2018/00351—Heart
- A61B2018/00357—Endocardium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00345—Vascular system
- A61B2018/00351—Heart
- A61B2018/00363—Epicardium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
- A61B2018/00577—Ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00773—Sensed parameters
- A61B2018/00875—Resistance or impedance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
- A61B34/20—Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
- A61B2034/2046—Tracking techniques
- A61B2034/2051—Electromagnetic tracking systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
- A61B34/20—Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
- A61B2034/2046—Tracking techniques
- A61B2034/2059—Mechanical position encoders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/392—Radioactive markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3933—Liquid markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3937—Visible markers
- A61B2090/395—Visible markers with marking agent for marking skin or other tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3954—Markers, e.g. radio-opaque or breast lesions markers magnetic, e.g. NMR or MRI
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3966—Radiopaque markers visible in an X-ray image
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3987—Applicators for implanting markers
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Otolaryngology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Electromagnetism (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Robotics (AREA)
- Optics & Photonics (AREA)
- Cardiology (AREA)
- Plasma & Fusion (AREA)
- Surgical Instruments (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Methods of performing surgical operations and associated devices are disclosed. An example method may include locating a first position on a first surface of a biological tissue; locating a second position on a second opposing surface of the biological tissue, the second position corresponding to the first position; and marking the second position on the second surface. The second surface may be generally opposite the first surface. An example method may include, after marking the second position, performing a therapeutic procedure on the biological tissue in the vicinity of the second position.
Description
- This application is a continuation of U.S. Nonprovisional application Ser. No. 16/869,157, now U.S. Pat. No. ______, which claims the benefit of U.S. Provisional Application No. 62/845,313, filed May 8, 2019, which is incorporated by reference.
- The present disclosure is directed to medical instruments and devices and related methods, and, more specifically, to surgical devices for locating and/or marking positions on biological tissues, such as the wall of the heart, and related methods.
- The present disclosure contemplates that some cardiac procedures may be performed substantially entirely from within the chambers of the heart, such as by a cardiac electrophysiologist using a catheter-based procedure. The present disclosure contemplates that other cardiac procedures may be performed substantially entirely from the exterior of the heart, such as by a cardiac surgeon accessing the heart via a skin incision. The present disclosure contemplates that a hybrid cardiac surgical procedure may combine an interventional aspect (e.g., an endocardial approach via a catheter guided by fluoroscopy) with a surgical aspect (e.g., an epicardial approach via a skin incision guided by direct visualization or endoscopic camera).
- The present disclosure contemplates that surgical pens may be used to mark on a patient's skin; however, surgical pens are generally not optimal for internal use during surgical procedures. For example, the ink used in a surgical pen may rub or brush off of internal structures during the surgical procedure. Further, surgical pens are generally not configured for use during minimally invasive procedures. For example, surgical pens typically do not have appropriate dimensions to facilitate insertion into a surgical site via a thoracoscopic trocar.
- It is an aspect of the present disclosure to provide a method of performing an operation, including locating a first position on a first surface of a biological tissue; locating a second position on a second surface of the biological tissue, the second position corresponding to the first position; and/or marking the second position on the second surface.
- In a more detailed embodiment, locating the second position on the second surface may include electrically locating the second position on the second surface. Electrically locating the second position on the second surface may include emitting an electromagnetic signal by an instrument on the second surface, the instrument on the second surface including a sensor configured to detect changes in a signal amplitude influenced by an instrument on the first surface. Electrically locating the second position on the second surface may include measuring a closed-loop impedance between an instrument on the second surface and an opposing instrument on the first surface. Locating the second position on the second surface may include visually locating the second position on the second surface. Locating the second position on the second surface may include mechanically locating the second position on the second surface. Locating the second position on the second surface may include magnetically locating the second position on the second surface.
- In a more detailed embodiment, the second surface may be generally opposite the first surface. The method may include, after marking the second position, performing a therapeutic procedure on the biological tissue in the vicinity of the second position. Performing the therapeutic procedure may include ablating a portion of the biological tissue. Marking the second position may include marking a point on the second surface. Marking the second position may include marking a line on the second surface. Marking the second position may include marking an area on the second surface. Marking the area may include marking a perimeter of the area. Marking the area may include marking substantially all of an internal area defined by the perimeter. Marking the second position may include disposing a marker on the second surface. The marker may include a marking substance. The marking substance may include at least one of an ink and a dye. The marking substance may include a radionuclide. The marking substance may include a radiopaque substance. The marking substance may include a magnetic substance. The marker may include an object. The object may include a magnetic substance. The object may be electrically insulative and/or the method may include applying RF energy to the tissue while at least a portion of the tissue is protected from the RF energy by the marker. The object may be bioabsorbable. Disposing the marker on the second surface may include at least partially penetrating the second surface. Locating the second position may be performed without penetrating the biological structure. Marking the second position may include heating the tissue to create a lesion that is detectable on the second surface. Heating the tissue may include applying RF energy, microwave energy, and/or laser energy. The method may include visually detecting the lesion on the second surface. The method may include electrically detecting the lesion on at least one of the first surface and the second surface. Marking the second position may include applying cold to the tissue to create an ice formation that is detectable on the second surface. Applying cold to the tissue may include applying cold to the first surface and/or the second surface. The method may include visually detecting the at least one of the lesion and the ice formation on the second surface. The method may include mechanically detecting the ice formation on the second surface. Locating the second position may include distending the biological tissue by pushing on the first surface to form a protrusion on the second surface.
- In a more detailed embodiment, the biological tissue may include a heart wall, the first surface may include an endocardial surface, and/or the second surface may include an epicardial surface. Locating the first position may include locating a sinoatrial node, an atrioventricular node, a ganglionic plexi, and/or an arrhythmogenic area.
- In a more detailed embodiment, the biological tissue may include a heart wall, the first surface may include an epicardial surface, and/or the second surface may include an endocardial surface. Locating the first position may include locating a sinoatrial node, an atrioventricular node, a ganglionic plexi, and/or an arrhythmogenic area.
- In a more detailed embodiment, locating the first position on the first surface of the biological tissue may include electroanatomical mapping.
- It is an aspect of the present disclosure to provide a method of marking a biological tissue, including introducing a marking device into a surgical space, the marking device including an elongated shaft and an at least partially covered, distally disposed absorbent tip; exposing the tip; and/or marking the tissue by applying a marking substance from the tip to the tissue.
- In a more detailed embodiment, the marking substance may include at least one of an ink, a dye, a radionuclide, a radiopaque substance, and a magnetic substance. The method may include, prior to introducing the marking device into the surgical space, loading the tip with a liquid. The liquid may include the marking substance. The tip may be pre-loaded with a dry form of the marking substance and/or loading the tip with the liquid may include hydrating the tip and the marking substance. The tip may include at least one microneedle and/or marking the tissue may include penetrating the tissue with the microneedle. The marking device may include a sheath slidably disposed on the shaft, the sheath being longitudinally movable between an extended configuration and a retracted configuration and/or exposing the tip may include withdrawing the sheath from the extended configuration to the retracted configuration. The sheath may be substantially transparent and/or the method may include, prior to exposing the tip, aligning a distal portion of the sheath with a portion of the tissue by viewing at least the portion of the tissue through the sheath. The tip may be longitudinally movable between an extended configuration and a retracted configuration and/or exposing the tip may include extending the tip from the retracted configuration to the extended configuration. The method may include reloading the tip with the marking substance by moving the tip from the extended configuration to the retracted configuration.
- In a more detailed embodiment, the method may include, after introducing the marking device into the surgical space, guiding the tip to a desired location using magnetic attraction, magnetic repulsion, and/or an impedance measurement of the tissue. The method may include, before marking the tissue, stabilizing the marking device. Stabilizing the marking device may include stabilizing the marking device using suction and/or stabilizing the marking device using magnetic attraction.
- It is an aspect of the present disclosure to provide a method of marking a biological tissue, including locating a position on a biological tissue; applying a patch at the position; and/or transferring a marking substance from the patch to the tissue.
- In a more detailed embodiment, the marking substance may include at least one of an ink and a dye. The marking substance may include a radionuclide. The marking substance may include a radiopaque substance. The marking substance may include a magnetic substance. The patch may include a substrate configured to hold the marking substance. The substrate may be constructed from a bioabsorbable material and/or the method may include leaving the patch in position on the tissue after a surgical procedure. The substrate may be constructed from a biocompatible material and/or the method may include removing the patch from the tissue before completion of a surgical procedure. The substrate may be constructed from a biocompatible material and/or the method may include leaving the patch in position on the tissue after a surgical procedure. The method may include providing the patch in a dry state. The method may include applying the patch in the dry state. The method may include, before applying the patch, hydrating the patch. The patch may include the substrate and a dry form of the marking substance and/or hydrating the patch may include hydrating the marking substance. Hydrating the patch may include hydrating the patch with a liquid form of the marking substance.
- It is an aspect of the present disclosure to provide a surgical device for marking a biological tissue, including an elongated shaft; a tip disposed distally on the elongated shaft, the tip comprising an absorbent material; and/or a sheath slidably disposed on the shaft, the sheath being longitudinally movable between an extended configuration and a retracted configuration. In the extended configuration, the sheath may at least partially cover a distal portion of the shaft and the tip. In the retracted configuration, at least a portion of the tip may be exposed.
- In a more detailed embodiment, at least a portion of the sheath may be substantially transparent. The tip may include at least one microneedle arranged to penetrate a target tissue. The tip may be configured to be loaded with a marking substance. The tip may be loaded with the marking substance. The marking substance may include at least one of an ink and a dye. The marking substance may include a radionuclide. The marking substance may include a radiopaque substance. The marking substance may include a magnetic substance. The marking substance may be a liquid. The marking substance may be in a dry state and/or the tip and the marking substance may be configured to be hydrated prior to use.
- It is an aspect of the present disclosure to provide a surgical device for marking a biological tissue, including an elongated shaft with a distally disposed tip, the tip comprising an absorbent material. The tip may be longitudinally movable between a retracted configuration and an extended configuration. In the retracted configuration, the tip may be positioned substantially within the shaft. In the extended configuration, at least a portion of the tip may be exposed.
- In a more detailed embodiment, the tip may be configured to be loaded with a marking substance. The tip may be loaded with the marking substance. The marking substance may include at least one of an ink and a dye. The marking substance may include a radionuclide. The marking substance may include a radiopaque substance. The marking substance may include a magnetic substance. The marking substance may be a liquid. The marking substance may be in a dry state and/or the tip and the marking substance may be configured to be hydrated prior to use.
- It is an aspect of the present disclosure to provide a patch for marking a biological tissue, including a substrate and/or a marking substance loaded in the substrate.
- In a more detailed embodiment, the substrate may be configured to transfer at least some of the marking substance to a biological tissue. The marking substance may include at least one of an ink and a dye. The marking substance may include a radionuclide. The marking substance may include a radiopaque substance. The marking substance may include a magnetic substance. The substrate may be constructed from a bioabsorbable material. The substrate may be constructed from a biocompatible material. The patch may include a dry form of the substrate and a dry form of the marking substance. The patch may be configured to be placed on a biological tissue without being pre-hydrated. The patch may be configured to hydrated before being placed on a biological tissue. The marking substance may include a liquid. The substrate may include a film. The substrate may be electrically insulative.
- It is an aspect of the present disclosure to provide a method of making a biological tissue marking device, including providing a substrate comprising at least one of a bioabsorbable material and a biocompatible material and/or loading a marking substance into the substrate.
- In a more detailed embodiment, absorbing the marking substance into the substrate may include absorbing a liquid marking substance into the substrate. The method may include, after loading the liquid marking substance into the substrate, dehydrating the substrate and the marking substance. The method may include, prior to use, hydrating the substrate and the marking substance. Loading the marking substance into the substrate may include loading a dry form of the marking substance into the substrate. The substrate may include a film and/or providing the substrate may include forming the film.
- In a more detailed embodiment, providing the substrate may include providing the substrate in a ready-to-use size and shape. Providing the substrate may include providing the substrate in a size larger than a desired use size and shape. The method may include cutting the substrate to the desired use size and shape.
- Example embodiments are described in conjunction with the accompanying drawing figures in which:
-
FIG. 1 is a partial cutaway view of a heart showing the approximate position of a sinoatrial node; -
FIGS. 2-7 are detailed cross-sectional views of a heart wall proximate the sinoatrial node; -
FIG. 8 is a cutaway view of an example sheathed kittner with a sheath in an extended configuration; -
FIG. 9 is a cutaway view of the sheathed kittner with the sheath in a retracted configuration; -
FIGS. 10 and 11 are cross-sectional views illustrating an example method of using a sheathed kittner to mark the epicardium; -
FIG. 12 is a side view of an example marking instrument in a retracted configuration; -
FIG. 13 is a side view of the marking instrument in an extended configuration; -
FIGS. 14 and 15 are partial cross-sectional views illustrating an example method of using a marking instrument to mark the epicardium; -
FIG. 16 is an isometric view of an example patch; -
FIG. 17 is a partial cross-sectional view illustrating an example method of applying a patch; -
FIG. 18 is a detailed cross-sectional view of a heart wall showing an RF ablation device creating a marker comprising a lesion on the second (epicardial) surface; -
FIG. 19 is a detailed cross-sectional view of a heart wall showing a cryosurgical device creating a marker comprising ice formation visible on the second (epicardial) surface; and -
FIG. 20 is an isometric view of a biological tissue with example markers thereon; all in accordance with at least some aspects of the present disclosure. - Example embodiments according to the present disclosure are described and illustrated below to encompass devices, methods, and techniques relating to medical and surgical procedures. Of course, it will be apparent to those of ordinary skill in the art that the embodiments discussed below are examples and may be reconfigured without departing from the scope and spirit of the present disclosure. It is also to be understood that variations of the example embodiments contemplated by one of ordinary skill in the art shall concurrently comprise part of the instant disclosure. However, for clarity and precision, the example embodiments as discussed below may include optional steps, methods, and features that one of ordinary skill should recognize as not being a requisite to fall within the scope of the present disclosure.
- The present disclosure contemplates that some surgical procedures may involve biological tissues that are accessible both from a first side and from a generally opposed second side. For example, during some hybrid cardiac procedures, both the interior surface of the heart wall (e.g., the endocardium) and the exterior surface of the heart wall (e.g., the epicardium) may be accessible. During some procedures, it may be advantageous to locate a particular position on the tissue from the first side and to perform a therapeutic procedure (e.g., ablation) from the second side. As used herein, “a position” may be a specific place or spot, such as a point, a line, a two-dimensional area, and/or a three-dimensional volume. As used herein, “to locate” may refer to an act of determining, finding, and/or identifying a position. Generally, the present disclosure includes devices for locating and/or marking positions on biological tissues, such as the wall of the heart, and related methods.
- Some example embodiments according to at least some aspects of the present disclosure may be used in connection with locating a position on a second side of a biological tissue (e.g., the epicardium) corresponding to and/or utilizing a position initially located on a first side of the tissue (e.g., the endocardium). For example, during a hybrid cardiac procedure, a cardiac electrophysiologist (“EP”) may locate the position of a particular anatomical structure based electrophysiological mapping performed on the endocardium (e.g., the interior surface of the heart wall). Then, a surgeon may locate and/or mark a corresponding position on the epicardium (e.g., the exterior surface of the heart wall), such as to guide acute therapy, staged therapy, and/or chronic postoperative follow-up therapy or diagnostics. For example, placement of one or more fiducial markers may facilitate future imaging studies, such as to confirm of the stability of a left atrial appendage occlusion clip applied during a hybrid left atrial appendage treatment.
- Particularly when a therapeutic procedure must be performed in a specific manner to include or avoid a certain portion of the tissue, it may be advantageous to locate and/or mark a position on the second side of the tissue that corresponds to the position initially located on the first side of the tissue. For example, the position of a portion of the tissue which is to be ablated may be located on the first side of the tissue, and a corresponding position may be marked on the second side of the tissue. Then, the marking may be used to help direct the ablation device at the portion of the tissue that is to be ablated. Alternatively, the position of a portion of the tissue which is not to be ablated may be located on the first side of the tissue, and a corresponding position may be marked on the second side of the tissue. Then, the marking may be used to direct the ablation device so as to avoid ablating the marked portion of the tissue. Some example markings may be durable and/or readily detectable to facilitate subsequent location of a marked position using the marking.
-
FIG. 1 is a partial cutaway view of aheart 10 showing the approximate position of a sinoatrial (“SA”)node 12 andFIGS. 2-7 are detailed cross-sectional views of aheart wall 14 proximate theSA node 12 illustrating example operations, all according to at least some aspects of the present disclosure. - Referring to
FIG. 1 , theSA node 12 is found in the heart wall 14 (e.g., myocardium) of theright atrium 16, laterally to the entrance to thesuperior vena cava 18. The cells of theSA node 12 produce electrical impulses that cause theheart 10 to contract. An example hybrid cardiac procedure may include treatment for an arrhythmia, such as inappropriate sinus tachycardia (“IST”), which may be caused by abnormal anatomy or physiology within the heart's conduction system. Such a procedure may include epicardial ablation in the vicinity of theSA node 12; however, the position of theSA node 12 may not be readily visually apparent when viewing the epicardial surface. - Referring to
FIGS. 1-3 , a physician (e.g., an EP) may use anelectrical mapping catheter 20 extending within the heart 10 (e.g., within the right atrium 16) to locate afirst position 24, such as a position associated with the patient'sSA node 12, on a first,endocardial side 22 of theheart wall 14. For example, the EP may use known electrophysiological/electroanatomical mapping techniques to locate theposition 24 of theSA node 12 on theendocardium 22. In other example embodiments, other portions of theheart wall 14 may be located, such as positions associated with an atrioventricular node, a ganglionic plexi, and/or an arrhythmogenic area. - Referring to
FIG. 4 , the EP may distend theheart wall 14 generally outward by pushing on theendocardium 22 using themapping catheter 20, forming aprotrusion 26 on the second,epicardial surface 28. Theprotrusion 26 may be visible (e.g., directly or using an instrument such as an endoscope) and/or mechanically detectable (e.g., palpable directly or using an instrument) on theepicardial side 28 of theheart wall 14, thereby indicating the correspondingsecond position 30 on theepicardium 28. It will be appreciated that any technique for correlating thefirst position 24 on theendocardial surface 22 with thesecond position 30 on theepicardial surface 28 may be used, including the alternative techniques described elsewhere herein. - In some alternative example embodiments, the
second position 30 may be located electrically, such as by using an epicardially positionedinstrument 21 including asensor 23. For example, similar to a proximity sensor, an instrument may be configured for sensing and interpreting signal amplitudes between the surfaces. For example,instrument 21 may emit an electromagnetic signal (e.g., a field or beam of electromagnetic radiation) on the second surface andsensor 23 may look for a changes in the return signal influenced by an instrument on the first surface (e.g., catheter 20) in order to correlate the tissue position between the two instruments. In other example embodiments, theinstrument 21 andcatheter 20 may be configured to assess changes in tissue impedance across the tissue area between two opposing poles. For example, an instrument on the second surface (e.g., instrument 21) and an instrument on the first surface (e.g., catheter 20) may be used as a closed-loop system to detect tissue impedance therebetween.Instrument 21 andcatheter 20 may be aligned on their respective tissue surfaces and translated across the tissue area to assess changes in impedance, which may correlate to structures or areas of therapeutic interest in the tissue. For example, asecond position 30 indicated by non-focal tissue structure (e.g., SA node) may be located by detecting a change of impedance of the tissue in that region (in relation to the surrounding tissue) between the poles ofinstrument 21 andcatheter 20. It will be appreciated that in alternative example embodiments, similar electrical location of thesecond position 30 may be conducted with alternative arrangements of the instruments and/or sensors. For example, the elements positioned adjacent the first surface and the second surface may be reversed. - In some alternative example embodiments, the
second position 30 may be located magnetically. For example, thesensor 23 of the epicardially positionedinstrument 21 may be configured to detect one or more endocardially positioned magnets (e.g., magnets associated with the mapping catheter 20). In other example embodiments, one ormore magnets 25 in the epicardially positionedinstrument 21 may be configured to magnetically interact with (e.g., attract) one ormore magnets 27 associated with themapping catheter 20. - Referring to
FIG. 5 , the same or another physician (e.g., a cardiac surgeon) may mark thesecond position 30 on theepicardial side 28 of theheart wall 14, such as by disposing amarker 32 on theepicardial surface 28 at thesecond position 30, which may be indicated by theprotrusion 26. It will be appreciated that any marking device and/or marking technique, such as those described elsewhere herein, may be utilized to facilitate marking thesecond position 30 with themarker 32. Generally, as used herein, “marker” may refer to an indicator of a position. A marker may include, for example, a marking substance (e.g., permanent or semi-permanent ink or dye, bioabsorbable/dissolvable patch, permanent fiducial marker which may or may not be radio-opaque) applied to a particular portion of a surface, an object placed on the surface, and/or a tissue lesion. In some example procedures, a physician may perform epicardial electrical mapping, such as before and/or after disposing themarker 32 on theepicardial surface 28. - Referring to
FIG. 6 , themapping catheter 20 may be at least partially withdrawn, which may remove theprotrusion 26. Themarker 32 may remain visible or otherwise detectable on theepicardial surface 28 at thesecond position 30. - Referring to
FIGS. 1 and 7 , the surgeon may perform a therapeutic procedure, such as ablating portions of the heart wall proximate theSA node 12, from the epicardial 28 side of theheart wall 14. The surgeon may access theepicardium 28 via anincision 36 through theskin 38. The surgeon may utilize themarker 32 to direct a treatment device, such as anablation device 34, to ablate the desired portions of theheart wall 14. In some procedures for treating IST, it may be desirable to ablate a portion of theheart wall 14 in the vicinity of, but not including, the portion of theheart wall 14 comprising theSA node 12. Accordingly, the surgeon may direct theablation device 34 so that it ablates theheart wall 14 near themarker 32, while avoiding the portion of the heart wall marked by themarker 32. Alternatively, such as in other procedures or if it is necessary to ablate theSA node 12, the surgeon may direct theablation device 34 so that it ablates a portion of the heart wall marked by themarker 32. Some example embodiments may be used in connection with longer-term follow-up procedures or diagnostics. For example, future procedures facilitated by amarker 32 may be surgical, endocardial/interventional, and/or radiotherapeutic in nature. - Although the foregoing description focused on the location and marking of positions associated with the SA node, it will be appreciated that alternative embodiments according to at least some aspects of the present disclosure, which may include similar devices and/or operations, may be utilized in connection with procedures involving other portions of the heart and/or other biological tissues. Also, although the foregoing description focused on marking a second position on a relatively outer surface (e.g., epicardium) based on a first location on a relatively inner surface (e.g., endocardium), it will be appreciated that various alternative example embodiments according to at least some aspects of the present disclosure may be utilized to mark a second position on a relatively inner surface (e.g., endocardium) based on a first location on a relatively outer surface (e.g., epicardium) using substantially similar instruments and techniques.
-
FIG. 8 is a cutaway view of an example sheathedkittner 100 with asheath 102 in an extended configuration andFIG. 9 is a cutaway view of the sheathedkittner 100 with thesheath 102 in a retracted configuration, according to at least some aspects of the present disclosure. Generally, the illustrative sheathedkittner 100, an example marking device, includes anelongated shaft 104 with anabsorbent tip 106 disposed distally thereon. Thetip 106 may comprise an absorbent fabric, for example. Asheath 102 is disposed around theshaft 104 and is longitudinally movable (e.g., slidable) between an extended configuration (FIG. 8 ) and a retracted configuration (FIG. 9 ). In the extended configuration, thesheath 102 at least partially covers the distal portion of theshaft 104 and thetip 106. In the retracted configuration, at least a portion of thetip 106 is exposed and is arranged to contact the tissue that is intended to be marked (the “target tissue”). - Generally, the
sheath 102 may be configured so that, in the extended configuration, thesheath 102 prevents thetip 106 from contacting tissues or surfaces other than the target tissue. For example, a distal portion of thesheath 102 may extend distally beyond thetip 106. In some example embodiments, at least a portion of thesheath 102 may be substantially transparent. This may allow the user to visualize the relative position of theendoscopic kittner 100 in relation to the target tissue. The sheath may also contain features such as an insufflation seal to prevent loss of pressure from the chest cavity during the procedure, visible depth index markers (radiopaque or otherwise), a friction feature to hold the sheath in a relative position to the kittner, or a handle, among others. - The
absorbent tip 106 may be dipped in or otherwise loaded with a liquid marking substance (e.g., ink or dye, radiopaque contrast media) for marking tissue. For example, thekittner 100 may be supplied with thetip 106 pre-wetted with the marking substance. In other embodiments, thetip 106 may be pre-loaded with a dry marking substance, which may be hydrated at the time of use. In other embodiments, a cartridge containing a liquid marking substance may be supplied with thekittner 100, and thetip 106 may be loaded with the marking substance at the time of use. In some example embodiments, thesheath 102 may serve as an ink well for the marking substance loaded kittner as the marking substance is wicked up the sheath. By drawing thetip 106 back into thesheath 102, thetip 106 may be at least partially reloaded with the marking substance. Generally, thetip 106 may be configured to carry sufficient marking substance to allow the user to create small “point” marks and/or to create more complex shapes on the target tissue as desired. - Generally, the sheathed
kittner 100 may be prepared for use, such as by loading thetip 106 with marking substance and/or placing thesheath 102 in the extended configuration (FIG. 8 ). The sheathedkittner 100 may be introduced into the surgical space, such as through a minimally invasive surgical access device (e.g., a sheath or trocar) or directly through a skin incision. Once in the surgical space, thesheath 102 may be advanced to the target tissue and aligned to direct the marking substance from thetip 106 at a desired position on the target tissue. The user may press and hold thesheath 102 against the target tissue. Thesheath 102 may be withdrawn to the retracted configuration (FIG. 9 ), exposing thetip 106, and thetip 106 may be used to mark the target tissue by applying the marking substance (e.g., ink) to the target tissue. Thesheath 102 may be returned to the extended configuration (FIG. 8 ), and the sheathedkittner 100 may be withdrawn from the surgical field. - The sheathed kittner 100 in
FIG. 9 includesoptional microneedles 108, which may be configured to at least partially penetrate the target tissue, which may facilitate application of the marking substance below the surface of the target tissue in a manner similar to a tattoo. -
FIGS. 10 and 11 are cross-sectional views illustrating an example method of using a sheathedkittner 100 to mark theepicardium 28, according to at least some aspects of the present disclosure. In this example, the sheathedkittner 100 is used to apply themarker 32 at thesecond position 30 associated with theSA node 12 as described above in connection withFIGS. 2-7 . Referring toFIG. 10 , the sheathedkittner 100, with thesheath 102 in the extended configuration, may be advanced to align the distal portion of thesheath 102 with theprotrusion 26 indicating thesecond position 30, which may comprise the target tissue. Then, theshaft 104 may be moved distally relative to thesheath 102 to cause thetip 106 to contact the second surface (e.g., epicardium) 28 at thesecond position 30, disposing themarker 32 comprising the marking substance (e.g., ink) from thetip 106 thereon as shown inFIG. 11 . - It will be appreciated that various illustrative sheathed
kittners 100 according to the present disclosure may be used to mark positions, such as thesecond position 30, in any desired size or shape. A sheathedkittner 100 may be used to mark a point, a line, and/or a two-dimensional area, for example. -
FIG. 12 is a side view of anexample marking instrument 200 in a retracted configuration andFIG. 13 is a side view of the markinginstrument 200 in an extended configuration, according to at least some aspects of the present disclosure. Generally, theillustrative marking instrument 200, an example marking device, includes anelongated shaft 202 with a distally disposedtip 204. Thetip 204 may comprise an absorbent fabric, for example. Thetip 204 may be longitudinally movable (e.g., slidable) between the retracted configuration (FIG. 12 ) and the extended configuration (FIG. 13 ). Positioning of the movable component may be controlled by a spring-loadedbutton 206, which may be disposed proximally, such as on ahandle 208. Extension limit of the moving component may be achieved with detents on thebutton component 206 which mate with thehandle component 208. In the retracted configuration, thetip 204 is positioned substantially within theshaft 202 so that thetip 204 does not mark adjacent tissues. In the extended configuration, at least a portion of thetip 204 is exposed (e.g., extends distally beyond the shaft 202) and is arranged to contact the target tissue. In some example embodiments, suction may be applied down the lumen of the device to assist with keeping the instrument in place during use. - The
tip 204 may be dipped in or otherwise loaded with a liquid marking substance (e.g., ink or dye) for marking tissue. For example, the markinginstrument 200 may be supplied with thetip 204 pre-wetted with the marking substance. In other embodiments, thetip 204 may be pre-loaded with a dry marking substance, which may be hydrated at the time of use. In other embodiments, a cartridge containing liquid marking substance may be supplied with the markinginstrument 200, and thetip 204 may be loaded with the marking substance at the time of use. Generally, thetip 204 may be configured to carry sufficient marking substance to allow the user to create small “point” marks or to create more complex shapes on the target tissue as desired. - Generally, the marking
instrument 200 may be prepared for use, such as by loading thetip 204 with the marking substance and/or placing thetip 104 in the retracted configuration (FIG. 12 ). The markinginstrument 200 may be introduced into the surgical space, such as through a minimally invasive surgical access device (e.g., a sheath or trocar) or directly through a skin incision. Once in the surgical space, theshaft 202 may be advanced to the target tissue and aligned to direct the marking substance from thetip 204 at a desired position on the target tissue. Thetip 204 may be extended (FIG. 13 ), and thetip 204 may be used to mark the target tissue by applying the marking substance to the target tissue. Thetip 204 may be returned to the retracted configuration (FIG. 12 ), and the markinginstrument 200 may be withdrawn from the surgical field. - In some example embodiments, a marking device, such as a marking
instrument 200, may include one or more features configured to facilitate guiding thetip 204 to the desired location. For example, referring toFIG. 12 , the markinginstrument 200 may include one or more sensors, such as animpedance sensor 210, which may be configured to sense the impedance of the target tissue. As another example, the markinginstrument 200 may include one ormore magnets 212, which may be attracted or repelled by a corresponding magnet associated with another instrument, such as amagnet 27 of a mapping catheter 20 (FIG. 4 ). Accordingly, after the markinginstrument 200 has been introduced into the surgical space, thetip 204 may be guided to a desired location using magnetic attraction, magnetic repulsion, and one or more impedance measurements of the tissue. It will be appreciated that similar guidance may be utilized in connection other example marking devices, such as the sheathed kittner described above. - In some example embodiments, a marking device, such as a marking
instrument 200, may include one or more features configured to facilitate stabilizing the markinginstrument 200. For example, referring toFIG. 13 , the markinginstrument 200 may include adistal suction opening 214 operatively connected to asuction source 216 via asuction tube 218. Application of suction may temporarily secure thedistal suction opening 214 to the tissue, thereby stabilizing the markinginstrument 200. As another example, themagnet 212 may be configured to be attracted to a corresponding magnet associated with another instrument, such as amagnet 27 of a mapping catheter 20 (FIG. 4 ), thereby stabilizing the markinginstrument 200. Accordingly, before marking the tissue, the markinginstrument 200 may be stabilized, such as by using suction and/or using magnetic attraction. It will be appreciated that similar stabilization may be utilized in connection other example marking devices, such as the sheathed kittner described above. -
FIGS. 14 and 15 are partial cross-sectional views illustrating an example method of using amarking instrument 200 to mark theepicardium 28, according to at least some aspects of the present disclosure. In this example, the markinginstrument 200 is used to apply amarker 32 at thesecond position 30 associated with theSA node 12 as described above in connection withFIGS. 2-7 . Referring toFIG. 14 , the markinginstrument 200, with thetip 204 in the retracted configuration, may be advanced into the surgical space near theprotrusion 26 indicating thesecond position 30, which may comprise the target tissue. Thetip 204 may be placed into the extended configuration. Referring toFIG. 15 , theshaft 202 may be manipulated to cause thetip 204 to contact the second surface (e.g., epicardium) 28 at thesecond position 30, disposing themarker 32 comprising the marking substance from thetip 204 thereon. - It will be appreciated that various
illustrative marking instruments 200 according to the present disclosure may be used to mark positions, such as thesecond position 30, in any desired size or shape. A markinginstrument 200 may be used to mark a point, a line, and/or a two-dimensional area, for example. -
FIG. 16 is an isometric view of anexample patch 300, according to at least some aspects of the present disclosure. Generally, theillustrative patch 300 is an object that can be placed on a biological tissue to mark a position. Thepatch 300 may be constructed of asubstrate 302. Thepatch 300 may comprise themarker 32 mentioned elsewhere herein. - In some example embodiments, the
substrate 302 may be constructed of one or more bioabsorbable materials.Such substrates 302 may be constructed from, for example, oxidized regenerated cellulose (ORC), polyglycolic acid (PGA) felt, collagen sponge (which may be coated with fibrinogen and/or thrombin), monofilament mesh (e.g., poly-4-hydroxybutyrate (P4HB)), and/or a biosynthetic web scaffold (e.g., polyglycolic acid (PGA) and trimethylene carbonate (TMC)). Some examplebioabsorbable substrates 302 may be radiopaque or may be doped to be radiopaque. In some example embodiments, thesubstrate 302 may comprise a film, which may be made by molding gelatin or oxidized regenerated cellulose, for example. Somepatches 300, such aspatches 300 comprisingsubstrates 302 constructed of bioabsorbable materials, may be placed on the biological tissue during a procedure and/or may be left in position on the tissue after the procedure. Somesuch patches 300 may be absorbed by the body over time. Alternatively,patches 300 may be removed from the biological tissue before the end of the procedure. - In some example embodiments, the
substrate 302 may be constructed of non-bioabsorbable materials. Somesuch substrates 302 may be constructed from biocompatible materials, for example, polyester, polyurethane, silicone, or a polyolefin (e.g., polypropylene or polyethylene). Some examplenon-bioabsorbable substrates 302 may be radiopaque or may be doped to be radiopaque. Somepatches 300, such aspatches 300 comprisingsubstrates 302 constructed of non-bioabsorbable materials, may be placed on the biological tissue during a procedure and/or may be removed from the biological tissue before the end of the procedure. Alternatively,patches 300 may be left in position on the tissue after the procedure. These forms may or may not initiate fibrotic infiltration for long term stability. - In some example embodiments, a
patch 300 may perform a function in connection with a treatment procedure. For example, apatch 300 comprising asubstrate 302 that is electrically insulative may be used in connection with an ablation procedure. Thepatch 300 may electrically insulate at least some of the underlying tissue from the by disrupting the electrical ablation signal. For example, electrical isolation may be achieved by incorporating coatings such as polyamideimide (reference Elantas PDG Elan-Film Insulation Sheet) or electrical grade polyester (reference Von Roll DMD-100 White Triplex Flexible Laminate Sheet) or incorporation of insulative materials such as polyimide into the formulation of the patch (reference DuPont Kapton HPP Low Shrinkage Polyimide Film Sheet Catalog). Accordingly, such apatch 300 may act as a protective patch for a portion of the underlying tissue, such as to prevent accidental ablation via the electrically insulative properties of the patch. - In some example embodiments, the
patch 300 may be provided in a dry state. Thepatch 300 may be hydrated before use, or it may be applied to the target tissue in a dry state. Alternatively, the patch may be provided in a hydrated state. - In some example embodiments, the
patch 300 may facilitate application of a marking substance, such as an ink ordye 304, to the biological tissue to comprise themarker 32. Specifically, thesubstrate 302 may be used to holddye 304 and/or facilitate applying thedye 304 to the target tissue. Generally, delivering thedye 304 using thepatch 300 may allow for moreconsistent marker 32 creation, potentially allowing more users to perform safer surgery, and/or potentially preventing thedye 304 from spreading or rubbing off of the target tissue. In a cardiovascular surgery, applying adye 304 using apatch 300 may improve safety for beating-heart procedures because it may reduce risk of damaging the heart with a potentially traumatic tip of a surgical marker or similar device. - In some example embodiments, the
patch 300 comprising thesubstrate 302 may be provided separately from thedye 304. Prior to use, aliquid dye 304 or adry dye 304 mixed with water may be absorbed into thesubstrate 302. Then, thepatch 300 may be placed on the target tissue. At least some of thedye 304 from thepatch 300 may transfer to the target tissue, thereby creating avisible marker 32 on the target tissue. - In other example embodiments, the
patch 300 comprising thesubstrate 302 and thedye 304 may be provided in a dry state. Prior to use, thepatch 300 may be wetted, such as with water. Then, thehydrated patch 300 may be placed on the target tissue. At least some of thedye 304 from thepatch 300 may transfer to the target tissue, thereby creating avisible marker 32 on the target tissue. - In other example embodiments, the
patch 300 comprising thesubstrate 302 and thedye 304 may be provided in a hydrated state. Thehydrated patch 300 may be placed on the target tissue, and at least some of thedye 304 from thepatch 300 may transfer to the target tissue, thereby creating avisible marker 32 on the target tissue. - In some example embodiments,
patches 300 configured to apply a marking substance, such asdye 304, to the target tissue may be applied to the target tissue, left in place to allow at least some of the marking substance to transfer to or act on the target tissue, and may be removed from the target tissue. -
Patches 300 may be configured to adhere to the target tissue in a hydrated and/or a dry state.Patches 300 may be formed in standard sizes and/or may be made into a specific size and/or shape based upon the target tissue and/or the patient. In some embodiments, thepatch 300 may be generally in the form of a small circle or oval as shown inFIG. 16 . However, the size of the dye delivery patch is not limited and may be a variety of shapes and/or sizes based upon the target tissue. For example, some patches 300 (e.g., substrate 302) may be provided in a ready-to-use size and shape. Alternatively, some patches 300 (e.g., substrate 302) may be provided in a size larger than a desired use size and/or shape. Then, a user may cut the patch 300 (e.g., substrate 302) to the desired use size and/or shape. - Some example embodiments are described herein as using various marking substances to provide a marker on a target tissue. Generally, it is within the scope of this disclosure to utilize any ink, dye, or other marking substance in connection with any embodiment described herein as using any such marking substance. For example, dyes such as methylene blue, gentian violet, Brilliant Blue FCF, and Evans Blue may be used as marking substances in various illustrative embodiments.
- In some example embodiments, a marker and/or marking substance may comprise a radiopaque substance, which may facilitate detection of a marker using fluoroscopy, for example. If the marker remains in the patient's body, the marker may be visible using fluoroscopy, for example, after the surgical procedure. Various known contrast agents may be used, such as iodine, including ioversal (a compound which contains organically bound iodine) or barium sulfate compounds. In some example embodiments, a marking substance may include an ink or dye to facilitate direct or endoscopic visibility as well as a radiopaque agent to facilitate fluoroscopic detection. In other embodiments, a marking substance may include only a visible marking substance (e.g., ink or dye) or only a radiopaque marking substance. Some example embodiments may include markers and/or marking substances comprising at least one radionuclide (for example, iodine-131 or technetium-99).
- Some example embodiments may include markers and/or marking substances comprising at least one magnetic substance (e.g., a ferromagnetic material). Generally, as used herein, “magnetic substance” may refer to a material that is itself magnetic or a material that is capable of being attracted to a magnet. Magnetic substances used in connection with markers and/or marking substances may be used to facilitate subsequent detection and/or location of a previously placed marker, for example. Additionally, in some example embodiments, the magnetic nature of a marker and/or marking substance comprising a magnetic substance may be utilized to facilitate application of the marking and/or marking substance at a particular position, such as by attraction of the magnetic substance on the second surface to a magnet on the first surface (e.g.,
magnet 27 associated with the mapping catheter 20). For example, a second position may be magnetically located by attracting a marker and/or marking substance to the second position using a magnet at the first position on the first surface. -
FIG. 17 is a partial cross-sectional view illustrating an example method of applying apatch 300, according to at least some aspects of the present disclosure. In this example, thepatch 300 may comprise themarker 32 that is disposed at thesecond position 30 associated with theSA node 12 as described above in connection withFIGS. 2-7 , or thepatch 300 may facilitate delivery of a marking substance that comprises themarker 32. Thepatch 300 may be disposed on theepicardial surface 28 using a surgical instrument, such as agrasper 306. - In some example embodiments, the
marker 32 may comprise a tissue lesion, such as a lesion created by a radiofrequency (“RF”) ablation device and/or a cryosurgical device.FIG. 18 is a detailed cross-sectional view of aheart wall 14 showing anRF ablation device 40 creating amarker 32 comprising a lesion on the second (epicardial)surface 28, according to at least some aspects of the present disclosure. In some example embodiments, the RF ablation may be performed at a relatively low energy level. Accordingly, the ablation may have no significant effect on the structure and/or function of the ablated tissue, other than to create the visuallyapparent marker 32. In some example embodiments, the lesion may heal over time.FIG. 19 is a detailed cross-sectional view of aheart wall 14 showing acryosurgical device 42 creating amarker 32 comprising ice formation visible on the second (epicardial)surface 28, according to at least some aspects of the present disclosure. In this example embodiment, thecryosurgical device 42 applies cold to the first (endocardial) surface 22 proximate thefirst position 24. As thecryosurgical device 42 is cooled, the tissue freezes creating ice formation, comprising themarker 32, becomes visible on thesecond surface 28. In alternative example embodiments, anRF ablation 40 device may be applied to the first (endocardial) surface 22 to create a lesion visible on the second (epicardial)surface 28 and/or acryosurgical device 42 may be applied to the second (epicardial)surface 28 to create a visually apparent ice formation. -
FIG. 20 is an isometric view of abiological tissue 400 withexample markers example markers markers kittner 100 or a markinginstrument 200, an object such as apatch 300, a marking substance (e.g., an ink or dye) applied by apatch 300, ice formation, and/or a tissue lesion, for example. Generally, markers described herein may be in the form of a circular or non-circular dot (e.g., point 32 a), a line (e.g.,straight line 32 b orcurved line 32 c), or an area (e.g.,perimeter 32 d or filledarea 32 e), for example. As used herein, “line” may refer to a long, thin shape, and a line may be substantially straight or may include one or more curves, bends, or angles. Markers according to the present disclosure may be standardized or may be sized and/or shaped specifically for particular patients and/or applications. - Following from the above description and invention summaries, it should be apparent to those of ordinary skill in the art that, while the methods and apparatuses herein described constitute example embodiments according to the present disclosure, it is to be understood that the scope of the disclosure contained herein is not limited to the above precise embodiments and that changes may be made without departing from the scope as defined by the following claims. Further, it is to be understood that, in general, any feature or aspect described in connection with one embodiment may be used in connection with any other embodiments. Likewise, it is to be understood that it is not necessary to meet any or all of the identified advantages or objects disclosed herein in order to fall within the scope of the claims, since inherent and/or unforeseen advantages may exist even though they may not have been explicitly discussed herein.
Claims (70)
1. A method of marking a biological tissue, the method comprising:
introducing a marking device into a surgical space, the marking device including an elongated shaft and an at least partially covered, distally disposed absorbent tip;
exposing the tip; and
marking the tissue by applying a marking substance from the tip to the tissue.
2. The method of claim 1 , wherein the marking substance comprises at least one of an ink, a dye, a radionuclide, a radiopaque substance, and a magnetic substance.
3. The method of claim 1 , further comprising, prior to introducing the marking device into the surgical space, loading the tip with a liquid.
4. The method of claim 3 , wherein the liquid comprises the marking substance.
5. The method of claim 3 ,
wherein the tip is pre-loaded with a dry form of the marking substance; and
wherein loading the tip with the liquid comprises hydrating the tip and the marking substance.
6. The method of claim 1 ,
wherein the tip comprises at least one microneedle; and
wherein marking the tissue comprises penetrating the tissue with the microneedle.
7. The method of claim 1 ,
wherein the marking device comprises a sheath slidably disposed on the shaft, the sheath being longitudinally movable between an extended configuration and a retracted configuration; and
wherein exposing the tip comprises withdrawing the sheath from the extended configuration to the retracted configuration.
8. The method of claim 7 ,
wherein the sheath is substantially transparent; and
wherein the method further comprises,
prior to exposing the tip, aligning a distal portion of the sheath with a portion of the tissue by viewing at least the portion of the tissue through the sheath.
9. The method of claim 1 ,
wherein the tip is longitudinally movable between an extended configuration and a retracted configuration; and
wherein exposing the tip comprises extending the tip from the retracted configuration to the extended configuration.
10. The method of claim 9 , further comprising reloading the tip with the marking substance by moving the tip from the extended configuration to the retracted configuration.
11. The method of claim 1 , after introducing the marking device into the surgical space, guiding the tip to a desired location using at least one of magnetic attraction, magnetic repulsion, and an impedance measurement of the tissue.
12. The method of claim 1 , further comprising, before marking the tissue, stabilizing the marking device.
13. The method of claim 12 , wherein stabilizing the marking device comprises at least one of stabilizing the marking device using suction and stabilizing the marking device using magnetic attraction.
14. A method of marking a biological tissue, the method comprising:
locating a position on a biological tissue;
applying a patch at the position; and
transferring a marking substance from the patch to the tissue.
15. The method of claim 14 , wherein the marking substance comprises at least one of an ink and a dye.
16. The method of claim 14 , wherein the marking substance comprises a radionuclide.
17. The method of claim 14 , wherein the marking substance comprises a radiopaque substance.
18. The method of claim 14 , wherein the marking substance comprises a magnetic substance.
19. The method of claim 14 , wherein the patch comprises a substrate configured to hold the marking substance.
20. The method of claim 19 ,
wherein the substrate is constructed from a bioabsorbable material; and
wherein the method comprises leaving the patch in position on the tissue after a surgical procedure.
21. The method of claim 19 ,
wherein the substrate is constructed from a biocompatible material; and
wherein the method comprises removing the patch from the tissue before completion of a surgical procedure.
22. The method of claim 19 ,
wherein the substrate is constructed from a biocompatible material; and
wherein the method comprises leaving the patch in position on the tissue after a surgical procedure.
23. The method of claim 19 , wherein the method comprises providing the patch in a dry state.
24. The method of claim 23 , wherein the method comprises applying the patch in the dry state.
25. The method of claim 23 , wherein the method comprises, before applying the patch, hydrating the patch.
26. The method of claim 23 ,
wherein the patch comprises the substrate and a dry form of the marking substance; and
wherein hydrating the patch comprises hydrating the marking substance.
27. The method of claim 23 , wherein hydrating the patch comprises hydrating the patch with a liquid form of the marking substance.
28. A surgical device for marking a biological tissue, the surgical device comprising:
an elongated shaft;
a tip disposed distally on the elongated shaft, the tip comprising an absorbent material; and
a sheath slidably disposed on the shaft, the sheath being longitudinally movable between an extended configuration and a retracted configuration;
wherein, in the extended configuration, the sheath at least partially covers a distal portion of the shaft and the tip; and
wherein, in the retracted configuration, at least a portion of the tip is exposed.
29. The surgical device of claim 28 , wherein at least a portion of the sheath is substantially transparent.
30. The surgical device of claim 28 , wherein the tip comprises at least one microneedle arranged to penetrate a target tissue.
31. The surgical device of claim 28 , wherein the tip is configured to be loaded with a marking substance.
32. The surgical device of claim 31 , wherein the tip is loaded with the marking substance.
33. The surgical device of claim 32 , wherein the marking substance comprises at least one of an ink and a dye.
34. The surgical device of claim 32 , wherein the marking substance comprises a radionuclide.
35. The surgical device of claim 32 , wherein the marking substance comprises a radiopaque substance.
36. The surgical device of claim 32 , wherein the marking substance comprises a magnetic substance.
37. The surgical device of claim 32 , wherein the marking substance is a liquid.
38. The surgical device of claim 32 ,
wherein the marking substance is in a dry state; and
wherein the tip and the marking substance are configured to be hydrated prior to use.
39. A surgical device for marking a biological tissue, the surgical device comprising:
an elongated shaft with a distally disposed tip, the tip comprising an absorbent material;
wherein the tip is longitudinally movable between a retracted configuration and an extended configuration;
wherein, in the retracted configuration, the tip is positioned substantially within the shaft; and
wherein, in the extended configuration, at least a portion of the tip is exposed.
40. The surgical device of claim 39 , wherein the tip is configured to be loaded with a marking substance.
41. The surgical device of claim 40 , wherein the tip is loaded with the marking substance.
42. The surgical device of claim 41 , wherein the marking substance comprises at least one of an ink and a dye.
43. The surgical device of claim 41 , wherein the marking substance comprises a radionuclide.
44. The surgical device of claim 41 , wherein the marking substance comprises a radiopaque substance.
45. The surgical device of claim 41 , wherein the marking substance comprises a magnetic substance.
46. The surgical device of claim 41 , wherein the marking substance is a liquid.
47. The surgical device of claim 41 ,
wherein the marking substance is in a dry state; and
wherein the tip and the marking substance are configured to be hydrated prior to use.
48. A patch for marking a biological tissue, the patch comprising:
a substrate; and
a marking substance loaded in the substrate.
49. The patch of claim 48 , wherein the substrate is configured to transfer at least some of the marking substance to a biological tissue.
50. The patch of claim 48 , wherein the marking substance comprises at least one of an ink and a dye.
51. The patch of claim 48 , wherein the marking substance comprises a radionuclide.
52. The patch of claim 48 , wherein the marking substance comprises a radiopaque substance.
53. The patch of claim 48 , wherein the marking substance comprises a magnetic substance.
54. The patch of claim 48 , wherein the substrate is constructed from a bioabsorbable material.
55. The patch of claim 48 , wherein the substrate is constructed from a biocompatible material.
56. The patch of claim 48 , wherein the patch comprises a dry form of the substrate and a dry form of the marking substance.
57. The patch of claim 56 , wherein the patch is configured to be placed on a biological tissue without being pre-hydrated.
58. The patch of claim 56 , wherein the patch is configured to hydrated before being placed on a biological tissue.
59. The patch of claim 48 , wherein the marking substance comprises a liquid.
60. The patch of claim 48 , wherein the substrate comprises a film.
61. The patch of claim 48 , wherein the substrate is electrically insulative.
62. A method of making a biological tissue marking device, the method comprising:
providing a substrate comprising at least one of a bioabsorbable material and a biocompatible material; and
loading a marking substance into the substrate.
63. The method of claim 62 , wherein absorbing the marking substance into the substrate comprises absorbing a liquid marking substance into the substrate.
64. The method of claim 63 , further comprising, after loading the liquid marking substance into the substrate, dehydrating the substrate and the marking substance.
65. The method of claim 64 , further comprising, prior to use, hydrating the substrate and the marking substance.
66. The method of claim 62 , wherein loading the marking substance into the substrate comprises loading a dry form of the marking substance into the substrate.
67. The method of claim 62 ,
wherein the substrate comprises a film; and
wherein providing the substrate comprises forming the film.
68. The method of claim 62 , wherein providing the substrate comprises providing the substrate in a ready-to-use size and shape.
69. The method of claim 62 , wherein providing the substrate comprises providing the substrate in a size larger than a desired use size and shape.
70. The method of claim 69 , wherein the method further comprises cutting the substrate to the desired use size and shape.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/243,988 US20230414296A1 (en) | 2019-05-08 | 2023-09-08 | Biological tissue position location and marking |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962845313P | 2019-05-08 | 2019-05-08 | |
US16/869,157 US11779397B2 (en) | 2019-05-08 | 2020-05-07 | Biological tissue position location and marking |
US18/243,988 US20230414296A1 (en) | 2019-05-08 | 2023-09-08 | Biological tissue position location and marking |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/869,157 Continuation US11779397B2 (en) | 2019-05-08 | 2020-05-07 | Biological tissue position location and marking |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230414296A1 true US20230414296A1 (en) | 2023-12-28 |
Family
ID=73046080
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/869,157 Active 2041-09-19 US11779397B2 (en) | 2019-05-08 | 2020-05-07 | Biological tissue position location and marking |
US18/243,988 Pending US20230414296A1 (en) | 2019-05-08 | 2023-09-08 | Biological tissue position location and marking |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/869,157 Active 2041-09-19 US11779397B2 (en) | 2019-05-08 | 2020-05-07 | Biological tissue position location and marking |
Country Status (5)
Country | Link |
---|---|
US (2) | US11779397B2 (en) |
EP (1) | EP3781025A4 (en) |
JP (2) | JP7279149B2 (en) |
CN (1) | CN112566544A (en) |
WO (1) | WO2020227540A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113171185A (en) * | 2021-04-26 | 2021-07-27 | 吉林大学 | Magnetic force guided minimally invasive detection tracking and position locking device for intestinal lesion markers |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62153229A (en) * | 1985-12-27 | 1987-07-08 | Nippon Oil Co Ltd | Skin marker |
US5909978A (en) * | 1993-11-15 | 1999-06-08 | Porex Surgical Inc. | Marker pen |
DE69534233T2 (en) | 1994-09-16 | 2005-10-27 | Ethicon Endo-Surgery, Inc., Cincinnati | DEVICES FOR DETERMINING AND MARKING TISSUE |
CA2187975C (en) | 1995-10-20 | 2001-05-01 | Lisa W. Heaton | Surgical apparatus and method for marking tissue location |
DE19615342C1 (en) | 1996-04-18 | 1997-10-09 | Siemens Ag | Therapy appts. with optical positioning device |
US5902310A (en) | 1996-08-12 | 1999-05-11 | Ethicon Endo-Surgery, Inc. | Apparatus and method for marking tissue |
US6030377A (en) * | 1996-10-21 | 2000-02-29 | Plc Medical Systems, Inc. | Percutaneous transmyocardial revascularization marking system |
US6527767B2 (en) | 1998-05-20 | 2003-03-04 | New England Medical Center | Cardiac ablation system and method for treatment of cardiac arrhythmias and transmyocardial revascularization |
US8498693B2 (en) | 1999-02-02 | 2013-07-30 | Senorx, Inc. | Intracorporeal marker and marker delivery device |
US6512943B1 (en) | 2000-05-22 | 2003-01-28 | Wisconsin Alumni Research Foundation | Combined ultrasound-radionuclide device for percutaneous ultrasound-guided biopsy and method of use |
AU2002239290A1 (en) | 2000-11-20 | 2002-06-03 | Senorx, Inc. | Tissue site markers for in vivo imaging |
DE60215819T2 (en) | 2001-08-03 | 2007-09-06 | Tyco Healthcare Group Lp, Norwalk | MARKER FOR USE WITH A TISSUE MARKING DEVICE |
US6743228B2 (en) | 2001-09-12 | 2004-06-01 | Manoa Medical, Inc. | Devices and methods for tissue severing and removal |
US6654629B2 (en) | 2002-01-23 | 2003-11-25 | Valentino Montegrande | Implantable biomarker and method of use |
US20040176759A1 (en) * | 2003-03-07 | 2004-09-09 | Subashini Krishnamurthy | Radiopaque electrical needle |
US6972022B1 (en) * | 2002-03-27 | 2005-12-06 | Michael Griffin | Skin-marking device |
US6932813B2 (en) | 2002-05-03 | 2005-08-23 | Scimed Life Systems, Inc. | Ablation systems including insulated energy transmitting elements |
US7329414B2 (en) | 2002-05-03 | 2008-02-12 | Biopsy Sciences, Llc | Biodegradable polymer for marking tissue and sealing tracts |
US7493154B2 (en) * | 2002-10-23 | 2009-02-17 | Medtronic, Inc. | Methods and apparatus for locating body vessels and occlusions in body vessels |
US6994712B1 (en) | 2002-11-12 | 2006-02-07 | Biopsy Sciences, Llc | Bioabsorbable marker having external anchoring means |
US7877133B2 (en) | 2003-05-23 | 2011-01-25 | Senorx, Inc. | Marker or filler forming fluid |
US20060069385A1 (en) | 2004-09-28 | 2006-03-30 | Scimed Life Systems, Inc. | Methods and apparatus for tissue cryotherapy |
US20060247516A1 (en) | 2005-04-08 | 2006-11-02 | Hess Christopher J | Tissue marker and method for use |
US8052658B2 (en) | 2005-10-07 | 2011-11-08 | Bard Peripheral Vascular, Inc. | Drug-eluting tissue marker |
US7702378B2 (en) | 2005-11-17 | 2010-04-20 | Breast-Med, Inc. | Tissue marker for multimodality radiographic imaging |
CA2574934C (en) | 2006-01-24 | 2015-12-29 | Sherwood Services Ag | System and method for closed loop monitoring of monopolar electrosurgical apparatus |
US20080009718A1 (en) | 2006-05-11 | 2008-01-10 | Zohman Gary L | Implements and methods for applying radiopaque markings |
US20080071208A1 (en) | 2006-09-20 | 2008-03-20 | Voegele James W | Dispensing Fingertip Surgical Instrument |
EP3542748B1 (en) | 2006-12-12 | 2023-08-16 | C. R. Bard, Inc. | Multiple imaging mode tissue marker |
ES2432572T3 (en) | 2006-12-18 | 2013-12-04 | C.R. Bard, Inc. | Biopsy marker with imaging properties generated in situ |
US8039193B2 (en) | 2007-09-13 | 2011-10-18 | Performance Indicator Llc | Tissue markings and methods for reversibly marking tissue employing the same |
US20090217932A1 (en) | 2008-03-03 | 2009-09-03 | Ethicon Endo-Surgery, Inc. | Intraluminal tissue markers |
ES2843628T3 (en) | 2009-06-26 | 2021-07-19 | Cianna Medical Inc | System for locating markers or tissue structures within a body |
ES2910440T3 (en) | 2010-11-16 | 2022-05-12 | Tva Medical Inc | Devices to form a fistula |
US9277872B2 (en) * | 2011-01-13 | 2016-03-08 | Rhythmia Medical, Inc. | Electroanatomical mapping |
US20120191081A1 (en) * | 2011-01-25 | 2012-07-26 | Medtronic, Inc. | Method and Apparatus for Regulating The Formation Of Ice On A Catheter |
WO2013101641A2 (en) | 2011-12-29 | 2013-07-04 | Rotation Medical, Inc. | Anatomical location markers and methods of use in positioning sheet-like materials during surgery |
US9150045B2 (en) | 2012-01-31 | 2015-10-06 | Novadaq Technologies Inc. | Method and device for surgical marking |
US8740919B2 (en) * | 2012-03-16 | 2014-06-03 | Ethicon, Inc. | Devices for dispensing surgical fasteners into tissue while simultaneously generating external marks that mirror the number and location of the dispensed surgical fasteners |
US20130289389A1 (en) | 2012-04-26 | 2013-10-31 | Focal Therapeutics | Surgical implant for marking soft tissue |
KR101380189B1 (en) | 2012-06-27 | 2014-04-17 | 방시열 | Needle unit for skin procedure |
US20140018663A1 (en) | 2012-07-16 | 2014-01-16 | Endomagnetics Ltd. | Magnetic Marker for Surgical Localization |
WO2015058007A1 (en) * | 2013-10-16 | 2015-04-23 | Medwerks, Llc | Atraumatic medical device |
JP6929665B2 (en) | 2016-05-30 | 2021-09-01 | キヤノンメディカルシステムズ株式会社 | Probe adapter, ultrasonic probe, and ultrasonic diagnostic equipment |
JP6760370B2 (en) | 2016-06-09 | 2020-09-23 | 株式会社島津製作所 | Near infrared imaging device |
US10398527B2 (en) | 2016-08-11 | 2019-09-03 | Terumo Cardiovascular Systems Corporation | Surgical tissue marking device with dryer |
-
2020
- 2020-05-07 WO PCT/US2020/031889 patent/WO2020227540A1/en unknown
- 2020-05-07 EP EP20803049.4A patent/EP3781025A4/en active Pending
- 2020-05-07 JP JP2021502754A patent/JP7279149B2/en active Active
- 2020-05-07 CN CN202080003404.XA patent/CN112566544A/en active Pending
- 2020-05-07 US US16/869,157 patent/US11779397B2/en active Active
-
2023
- 2023-05-09 JP JP2023077359A patent/JP2023095987A/en active Pending
- 2023-09-08 US US18/243,988 patent/US20230414296A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3781025A1 (en) | 2021-02-24 |
US20200352656A1 (en) | 2020-11-12 |
EP3781025A4 (en) | 2022-01-26 |
JP7279149B2 (en) | 2023-05-22 |
US11779397B2 (en) | 2023-10-10 |
JP2022531033A (en) | 2022-07-06 |
WO2020227540A1 (en) | 2020-11-12 |
CN112566544A (en) | 2021-03-26 |
JP2023095987A (en) | 2023-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8801707B2 (en) | Method and devices for treating atrial fibrillation by mass ablation | |
AU2002315167B2 (en) | Methods and devices for ablation | |
AU775394B2 (en) | Apparatus and method for ablating tissue | |
US20230414296A1 (en) | Biological tissue position location and marking | |
AU2002315167A1 (en) | Methods and devices for ablation | |
US11045251B2 (en) | Gastric tube for ablation procedures | |
KR20200121831A (en) | Configuration and method for guiding the endoscopic device | |
Dixit et al. | Role of contact and noncontact mapping in the curative ablation of tachyarrhythmias | |
US20200214769A1 (en) | Localization systems and methods of use | |
KROKHALEVA et al. | Principles of Mapping and Ablation | |
Valderrabano et al. | Creating transmural, linear epicardial ablation lesions via a non-surgical, percutaneous, subxyphoid, electrogram-guided approach | |
CN117481834A (en) | Size positioning method for mapping lung nodules on body surface | |
Liem | ELECTROANATOMICAL MAPPING USING THE CARTO® SYSTEM | |
Krist et al. | 2 Development of a novel linear laser catheter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT, ILLINOIS Free format text: SECURITY INTEREST;ASSIGNORS:ATRICURE, INC.;ATRICURE, LLC.;REEL/FRAME:066267/0896 Effective date: 20240105 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |